Cannabinoids led to significant improvements in neuropsychiatric symptoms of dementia as measured by several instruments (Cohen Mansfield Agitation Inventory, Neuropsychiatric Inventory, nocturnal actigraphy) and were well tolerated.
Systematic review + meta-analysis of cannabinoids for neuropsychiatric symptoms (NPS) in dementia; k=9 studies (n=205, 44% female, 78±7 years, 85% Alzheimer's). Cannabinoids led to significant improvements on the Cohen-Mansfield Agitation Inventory (SMD=-0,80; 95% CI -1,45 to -0,16), Neuropsychiatric Inventory (SMD=-0,61; CI -1,07 to -0,15) and nocturnal actigraphy (SMD=-1,05; CI -1,56 to -0,54). Completion rate 93% (193/205), no serious treatment-related adverse events. Efficacy was associated with baseline dementia severity and dose.
The highest of four GRADE levels, the effect estimate is very reliable.
The impediment to action advances action.